Dolutegravir for the Treatment of HIV in Patients with Tuberculosis in Kwazulu-Natal South Africa
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
Emerging Global Leader
Project Information in NIH RePORTER
Dolutegravir for the Treatment of HIV in Patients with Tuberculosis in Kwazulu-Natal South Africa
Principal Institution
Center for the AIDS Program of Research in South Africa (CAPRISA)
Principal Investigator(s) (PI)
Naidoo, Anushka
Project Contact Information
Email: anushka.naidoo@caprisa.org
Year(s) Awarded
2019-2024
Country
South Africa
Collaborators
Johns Hopkins University
Project Description
The World Health Organization recommends the antiretroviral drug dolutegravir as first-line treatment of HIV. However there is some uncertainty regarding its optimal use in patients with HIV-TB co-infection who are taking tuberculosis (TB) drugs due to some drug-drug interactions that may reduce dolutegravir efficacy. This study aims to fill this knowledge gap by understanding the impact of drug interactions with TB drugs on dolutegravir drug concentrations, adherence, and treatment outcomes. The study will be conducted in a high HIV-TB burden setting in KwaZulu-Natal South Africa.
Related World Regions / Countries
Related Global Health Research Topics